PVLA 8-K: SEC filing

Palvella Therapeutics

Filed with the SEC on · accession 0001193125-26-467823

PVLA filed a 8-K (current report) with the SEC on Nov 19, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Summary of the filing

Palvella Therapeutics announced the third product candidate from its QTORIN platform, QTORIN Docetaxel, for the treatment of Extramammary Paget's disease, and hosted an investor conference call to present the program.

Key details

RegistrantPalvella Therapeutics, Inc.
Chief financial officerMatthew Korenberg

✦ Ask GOAX AI about this filing — what it means for PVLA, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for PVLA?

Click here

Frequently asked questions

What did PVLA file with the SEC on Nov 19, 2026?

PVLA filed a 8-K (SEC filing). Palvella Therapeutics announced the third product candidate from its QTORIN platform, QTORIN Docetaxel, for the treatment of Extramammary Paget's disease, and hosted an investor conference call to present the program.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other PVLA SEC filings

Get alerts when PVLA files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days